Physician profile
Vinod Thakkar
NPI 1497717185
$2,118.02
in general payments reported to CMS, 2019-2025
26 companies · $91.42 in 2025
The $91.42 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $271 · 2021: $559 · 2022: $306 · 2023: $122 · 2024: $416 · 2025: $91.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $958.23 | 2019-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $144.85 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $136.06 | 2024 | Rezdiffra |
| Pfizer INC. | $123.36 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.10 | 2019-2022 | |
| Janssen Biotech, INC. | $80.93 | 2020-2021 | |
| Vivus LLC | $52.96 | 2021-2024 | Pancreaze |
| Fujifilm Healthcare Americas Corporation | $52.86 | 2024 | Fujifilm |
| Takeda Pharmaceuticals U.S.A., INC. | $50.73 | 2021-2022 | |
| Celgene Corporation | $43.80 | 2022 | |
| Axonics, INC. | $42.87 | 2021-2024 | Axonics |
| Amag Pharmaceuticals, INC. | $38.61 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $33.30 | 2022-2023 | Dupixent |
| Exact Sciences Corporation | $32.29 | 2025 | The Cologuard Plus Collection Kit |
| Genzyme Corporation | $28.55 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $28.07 | 2019 | |
| Mauna Kea Technologies, INC. | $24.68 | 2024 | |
| Boston Scientific Corporation | $24.15 | 2021 | |
| Gilead Sciences, INC. | $21.32 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.26 | 2022 | |
| Ferring Pharmaceuticals INC. | $19.94 | 2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $14.55 | 2023 | Ocaliva |
| Mallinckrodt Hospital Products INC. | $14.36 | 2023 | Terlivaz |
| Medtronic, INC. | $13.25 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.06 | 2019 | |
| Ethicon US, LLC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Thakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.